TCM
ABBV icon

Tekla Capital Management’s AbbVie ABBV Stock Holding History

Tekla Capital Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-200,000
Closed -$11.7M – 117
2015
Q1 		$11.7M Buy
+200,000
New +$12.1M 0.46% 52

Other funds holding ABBV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Tekla Capital Management's ABBV Position: Q2 2023 in Review

Tekla Capital Management increased its AbbVie (ABBV) stake by 6.7% in Q2 2023, buying an estimated $4.99M and bringing the position to 545,629 shares worth $73.5M. The position accounts for 2.88% of the portfolio, ranked #9.

Tekla Capital Management first reported a position in ABBV in Q3 2014 and has held it in 36 quarters since. The position peaked at $88.9M in Q1 2022. 3,077 funds tracked by Wall St. Rank hold ABBV as of Q2 2023.

  • Tekla Capital Management held 545,629 shares of AbbVie worth $73.5M as of Q2 2023.
  • Tekla Capital Management bought 34,030 AbbVie shares in Q2 2023, an estimated $4.99M.
  • AbbVie made up 2.88% of Tekla Capital Management's portfolio in Q2 2023, its #9 holding.
  • Tekla Capital Management first reported a position in AbbVie in Q3 2014 and has held it in 36 quarters since.
  • Tekla Capital Management's AbbVie position peaked at $88.9M in Q1 2022.
  • 3,077 funds tracked by Wall St. Rank held AbbVie as of Q2 2023.

Based on Tekla Capital Management's 13F filing for Q2 2023, filed 10 Aug 2023.